The Impact of a Forced Non-Medical Switch of Inhaled Respiratory Medication Among Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Patient Survey on Experience with Switch, Therapy Satisfaction, and Disease Control

References

• Seven takeaways from the new 2017 CVS health and express scripts formulary exclusion lists, August 3, 2016. Available from: https://www.drugchannels.net/2016/08/seven-takeaways-from-new-2017-cvs.html. Accessed February 21, 2019.
   Google Scholar
• Kodjak A. Will your prescription meds be covered next year? Better check! Available from: http://www.npr.org/sections/health-shots/2016/08/15/489790412/will-your-prescription-meds-be-covered-next-year-better-check. Accessed February 21, 2019.
   Google Scholar
• Chambers JD, Rane PB, Neumann PJ. The impact of formulary drug exclusion policies on patients and healthcare costs. Am J Manag Care. 2016;22(8):524–531.
   Web of Science ®Google Scholar
• Nguyen E, Weeda ER, Sobieraj DM, Bookhart BK, Piech CT, Coleman CI. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32(7):1281–1290. doi:10.1185/03007995.2016.1170673
   PubMed Web of Science ®Google Scholar
• Tennessee Patient Stability Coalition, Global Healthy Living Foundation. Tennessee patient sentiment toward non-medical drug switching; February 2016. Available from: https://creakyjoints.org/wp-content/uploads/2018/10/GHLF-Tennessee_Patient_Sentiment.pdf. Accessed February 21, 2019.
   Google Scholar
• Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1. doi:10.1186/1471-2466-9-1
   PubMedGoogle Scholar
• Bjornsdottir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 2013;67(9):904–910.
   PubMed Web of Science ®Google Scholar
• Bjornsdottir US, Sigurethardottir ST, Jonsson JS, et al. Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β2-agonists in obstructive lung diseases: a population-based, observational study. Int J Clin Pract. 2014;68(7):812–819. doi:10.1111/ijcp.12473
   Web of Science ®Google Scholar
• Chrystyn H. Do patients show the same level of adherence with all dry powder inhalers? Int J Clin Pract. 2005;59(suppl 149):19–25. doi:10.1111/j.1368-504X.2005.00723.x
   Web of Science ®Google Scholar
• Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J. 2010;19(2):131–139. doi:10.4104/pcrj.2010.00009
   PubMedGoogle Scholar
• Braido F, Lavorini F, Blasi F, Baiardini I, Canonica GW. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601–2608. doi:10.2147/COPD.S79635
   PubMed Web of Science ®Google Scholar
• Klijn LS, Hiligsmann M, Evers S, Roman-Rodriguez M, Molen T, Van Boven J. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017;27:24. doi:10.1038/s41533-017-0022-1
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int Chron Obstruct Pulmon Dis. 2016;11:407–415. doi:10.2147/COPD.S91118
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005
   PubMed Web of Science ®Google Scholar
• Ballinger R, Friedemann C, Golics CJ, Lloyd A, Doyle S. Impact of non-consented switch and subsequent switch in asthma medication: qualitative study of patient perspective in the UK. Value Health. 2014;17(7):A602. Abstract PRS681. doi:10.1016/j.jval.2014.08.2089
   Web of Science ®Google Scholar
• SYMBICORT® (budesonide and formoterol fumarate dihydrate) [package insert]. Dunkerque, France: AstraZeneca Dunkerque Production; December, 2017
   Google Scholar
• Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005;4(1):41–52. doi:10.2165/00151829-200504010-00005
   PubMedGoogle Scholar
• Leidy NK, Mathias SD, Parasuraman BM, Patrick DL, Pathak D. Development and validation of an onset of effect questionnaire for patients with asthma. Allergy Asthma Proc. 2008;29(6):590–599. doi:10.2500/aap.2008.29.3164
   Web of Science ®Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Juniper EF, Bousquet J, Abetz L, Bateman ED, Committee G. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the asthma control questionnaire. Respir Med. 2006;100(4):616–621. doi:10.1016/j.rmed.2005.08.012
   PubMed Web of Science ®Google Scholar
• Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CAT) scores. BMC Pulm Med. 2011;11:42. doi:10.1186/1471-2466-11-42
   PubMed Web of Science ®Google Scholar
• Devane K, Gilbert I, Davis J, Fox K Disruption in care after a forced formulary switch in inhaled respiratory medications: evaluating the effects of a national Medicare Part D payer’s NDC block on budesonide/formoterol fumarate dihydrate. Oral presentation presented at: CHEST Annual Meeting; October 6–10, 2018; San Antonio, TX.
   Google Scholar
• Belhassen M, Langlois C, Laforest L, et al. Level of asthma controller therapy before admission to the hospital. J Allergy Clin Immunol Pract. 2016;4(5):877–883. doi:10.1016/j.jaip.2016.06.012
   PubMed Web of Science ®Google Scholar
• Braman SS, Carlin BW, Hanania NA, et al. Results of a pulmonologist survey regarding knowledge and practices with inhalation devices for COPD. Respir Care. 2018;63(7):840–848. doi:10.4187/respcare.05717
   PubMed Web of Science ®Google Scholar
• Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi:10.1038/s41533-017-0016-z
   PubMed Web of Science ®Google Scholar
• Dhand R, Mahler DA, Carlin BW, et al. Results of a patient survey regarding COPD knowledge, treatment experiences, and practices with inhalation devices. Respir Care. 2018;63(7):833–839. doi:10.4187/respcare.05715
   PubMed Web of Science ®Google Scholar
• Hanania NA, Braman S, Adams SG, et al. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstr Pulm Dis. 2018;5(2):111–123. doi:10.15326/jcopdf.5.2.2017.0168
   PubMed Web of Science ®Google Scholar
• Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin Drug Deliv. 2014;11(3):365–378. doi:10.1517/17425247.2014.873402
   PubMed Web of Science ®Google Scholar
• Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2017;12:59–71. doi:10.2147/COPD.S117196
   PubMed Web of Science ®Google Scholar
• Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184–191. doi:10.4168/aair.2012.4.4.184
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Price DB, Molimard M, et al. Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulm Med. 2016;16:12. doi:10.1186/s12890-016-0169-5
   PubMed Web of Science ®Google Scholar
• Norderud Lærum B, Telg G, Stratelis G. Need of education for dry powder inhaler storage and retention – a patient-reported survey. Multidiscip Respir Med. 2016;11(1):21. doi:10.1186/s40248-016-0057-0
   PubMedGoogle Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179. doi:10.1089/jamp.2012.0987
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Feldman G, Korenblat P, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014;108(8):1171–1179. doi:10.1016/j.rmed.2014.05.008
   PubMed Web of Science ®Google Scholar
• Lotvall J, Bateman ED, Busse WW, et al. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014;13(1):9. doi:10.1186/1477-5751-13-9
   PubMedGoogle Scholar
• Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144(4):1222–1229. doi:10.1378/chest.13-0178
   PubMed Web of Science ®Google Scholar
• Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288–1293. doi:10.1016/j.jaci.2004.09.028
   PubMed Web of Science ®Google Scholar
• Corrao G, Arfe A, Nicotra F, et al. Persistence with inhaled corticosteroids reduces the risk of exacerbation among adults with asthma: a real-world investigation. Respirology. 2016;21(6):1034–1040. doi:10.1111/resp.12791
   Web of Science ®Google Scholar
• Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–1191 e1182. doi:10.1016/j.jaci.2011.09.011
   PubMed Web of Science ®Google Scholar
• Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–577. doi:10.1164/rccm.200906-0907OC
   PubMed Web of Science ®Google Scholar
• Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–220. doi:10.1016/j.anai.2013.06.008
   PubMed Web of Science ®Google Scholar
• Kaiser H, Parasuraman B, Boggs R, Miller CJ, Leidy NK, O’Dowd L. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids. Ann Allergy Asthma Immunol. 2008;101(3):295–303. doi:10.1016/S1081-1206(10)60495-4
   PubMed Web of Science ®Google Scholar